Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies

DOI PDF 被引用文献2件
  • Elias J. Anaissie
    From the Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock; Centraalbureau voor Schimmelcultures, Baarn, The Netherlands; Center for Infectious Diseases, University of Texas Medical School, Houston; John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock; and Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Shawna L. Stratton
    From the Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock; Centraalbureau voor Schimmelcultures, Baarn, The Netherlands; Center for Infectious Diseases, University of Texas Medical School, Houston; John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock; and Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • M. Cecilia Dignani
    From the Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock; Centraalbureau voor Schimmelcultures, Baarn, The Netherlands; Center for Infectious Diseases, University of Texas Medical School, Houston; John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock; and Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Choon-kee Lee
    From the Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock; Centraalbureau voor Schimmelcultures, Baarn, The Netherlands; Center for Infectious Diseases, University of Texas Medical School, Houston; John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock; and Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Richard C. Summerbell
    From the Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock; Centraalbureau voor Schimmelcultures, Baarn, The Netherlands; Center for Infectious Diseases, University of Texas Medical School, Houston; John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock; and Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • John H. Rex
    From the Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock; Centraalbureau voor Schimmelcultures, Baarn, The Netherlands; Center for Infectious Diseases, University of Texas Medical School, Houston; John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock; and Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Thomas P. Monson
    From the Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock; Centraalbureau voor Schimmelcultures, Baarn, The Netherlands; Center for Infectious Diseases, University of Texas Medical School, Houston; John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock; and Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Thomas J. Walsh
    From the Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock; Centraalbureau voor Schimmelcultures, Baarn, The Netherlands; Center for Infectious Diseases, University of Texas Medical School, Houston; John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock; and Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.

書誌事項

公開日
2003-04-01
DOI
  • 10.1182/blood-2002-02-0530
公開者
American Society of Hematology

この論文をさがす

説明

<jats:p>The incidence of mold infections in patients with hematologic malignancies continues to increase despite the widespread use of air filtration systems, suggesting the presence of other hospital sources for these molds. Water sources are known to harbor pathogenic molds. We examined samples from water, water surfaces, air, and other environment sources from a bone marrow transplantation unit with optimal air precautions. Molds (Aspergillus species, others) were recovered in 70% of 398 water samples, in 22% of 1311 swabs from plumbing structures and environmental surfaces, and in 83% of 274 indoor air samples. Microscopic examination of the water plumbing lines revealed hyphal forms compatible with molds. Four findings suggest that indoor airborne molds were aerosolized from the water: (1) higher mean airborne concentrations of molds in bathrooms (16.1 colony-forming units [CFU]/m3) than in patient rooms (7 CFU/m3) and hallways (8.6 CFU/m3;P = .00005); (2) a strong type and rank correlation between molds isolated from hospital water and those recovered from indoor hospital; (3) lack of seasonal correlation between the airborne mold concentration in outdoor and indoor air; and (4) molecular relatedness between a clinical strain and a water-related strain (previously reported). Hospital water distribution systems may serve as a potential indoor reservoir of Aspergillus and other molds leading to aerosolization of fungal spores and potential exposure for patients.</jats:p>

収録刊行物

  • Blood

    Blood 101 (7), 2542-2546, 2003-04-01

    American Society of Hematology

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ